Effects of androgens on bone in men and women

Clinical Reviews in Bone and Mineral Metabolism

Volumn 3, Issue 1, 2005, Pages 51-66

  McGriff Lee, Nayahmka ^a   Kalantaridou, Sophia N ^b   Pucino, Frank ^c   Calis, Karim Anton ^c,d,e  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b UNIVERSITY OF IOANNINA   (Greece)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^e SHENANDOAH UNIVERSITY   (United States)

Author keywords

Biochemical markers; Bone mineral density; DHEA; Hypogonadism; Osteopenia; Osteoporosis; Testosterone

Indexed keywords

ANABOLIC AGENT; ANDROGEN; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; BIOCHEMICAL MARKER; CONJUGATED ESTROGEN; CYCLOSPORIN; ESTRADIOL; ESTRATEST; ESTROGEN; FLUOXYMESTERONE; GESTAGEN; HYPOPHYSIS HORMONE; METHYLTESTOSTERONE; METRIBOLONE; NANDROLONE; NANDROLONE DECANOATE; NANDROLONE PHENPROPIONATE; OXANDROLONE; OXYMETHOLONE; PLACEBO; PRASTERONE; STANOZOLOL; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE ESTER; TESTOSTERONE PROPIONATE; THYROID HORMONE;

ACNE; ADENOMA; ALOPECIA; ANDROGEN THERAPY; BLEEDING; BONE DENSITY; BONE MASS; CHOLESTASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CLITORAL ENLARGEMENT; CYST; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; EDEMA; ERYTHEMA; ERYTHROCYTOSIS; FIRST PASS EFFECT; FRACTURE; GYNECOMASTIA; HIRSUTISM; HOARSENESS; HORMONE ACTION; HUMAN; HYPOGONADISM; INFECTION COMPLICATION; INFLAMMATION; INJECTION PAIN; INJECTION SITE REACTION; LARYNX DISORDER; LIBIDO DISORDER; LIPID BLOOD LEVEL; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER HYPERPLASIA; LIVER TOXICITY; LIVER TUMOR; NAUSEA; NONHUMAN; OLIGOSPERMIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT MONITORING; PELIOSIS HEPATIS; PHALLIC ENLARGEMENT; PHYSIOLOGY; PRIAPISM; PROSTATE CANCER; PROSTATE HYPERTROPHY; PRURITUS; PURPURA; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SKIN IRRITATION; SKIN MANIFESTATION; SLEEP APNEA SYNDROME; TESTIS ATROPHY; THROMBOGENESIS; VIRILIZATION; VOICE DEEPENING; VOMITING;

EID: 26244449466     PISSN: 15348644     EISSN: None     Source Type: Journal    
DOI: 10.1385/bmm:3:1:051     Document Type: Review

References (72)

1. Balasch J. 2003 Sex steroids and bone: current perspectives. Hum Reprod Update 9:207-222.
2. Morales AJ, Nolan JJ, Nelson JC, Yen SS. 1994 Effects of replacement dose of dihydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78:1360-1367.
3. Yanase T, Suzuki S, Goto K, et al. 2003 Aromatase in bone: roles of vitamin D3 and androgens. J Ster Biochem Mol Biol 86:393-397.
4. Colvard DS, Eriksen PE, Keeling PE. 1989 Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA 86:854-857.
5. Riggs BL, Khosla S, Melton LJ. 2002 Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279-302.
6. Eriksen EF, Colvard DS, Berg NJ, Graham et al. 1988 Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241:84-86.
7. Tenover JS. 1998 Androgen replacement therapy to reverse and/or prevent age-associated sarcopenia in men. Baillieres Clin Endocrinol Metab 12:419-425.
8. Szulc P, Claustrat B, Marchand F, Delmas PD. 2003 Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: The MINOS study. J Clin Endocrinol Metab 88:5240-5247.
9. Handelsman DJ. 2001 Androgen Action and Pharmacologic Uses. In: Endocrinology 4th ed. DeGroot LJ, Jameson JL, eds. W.B. Saunders, Philadelphia, pp.2232-2242.
10. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. 2001 Longitudinal effects of aging in serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 86:724-731.
11. Anonymous. 2000 Endocrine Society highlights importance of appropriate diagnosis and treatment of low testosterone. The Endocrine Society 82nd Annual Meeting, June 21-24.
12. Petak SM, Baskin HJ, Bergman DA, Dickey RA, Nankin HA. 1996 AACE clinical practice guidelines for the evaluation and treatment of hypogonadism in adult male patients. Endocrinol Pract 2:440-453.
13. Jackson JA, Riggs MW, Spiekerman AM. 1992 Testosterone deficiency as a risk factor for hip fractures in men: A case-control study. Am J Med Sci 304:4-8.
14. Abassi AA, Rudman D, Wilson CR, et al. 1995 Observations on nursing home residents with a history of hip fracture. Am J Med Sci 310:229-234.
15. Snyder PJ, Peachey H, Hannoush P, et al. 1999 Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966-1972.
16. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. 2001 Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 56:M266-M272.
17. Bebb R, Anawalt B, Wade J, et al. 2001 A randomized, double-blind, placebo-controlled trial of testosterone undecanoate administration in aging hypogonadal men: Effects on bone density and body composition [Abstract]. In: Proceedings of the Endocrine Society 83rd Annual Meeting, June 20-23, 2001, Denver, CO. Bethesda, MD, pp. 100-101.
18. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. 1996 Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81:4358-4365.
19. Finkelstein JS, Klibanski A, Neer RM, et al. 1989 Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 69:776-783.
20. Tenover JS. 1992 Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 75:1092-1098.
21. Amory JK, Watts NB, Easley KA, et al. 2004 Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89:503-510.
22. Wang C, Swerdloff RS, Iranmanesh A, et al. 2001 Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol 54:739-750.
23. Anderson FH, Francis RM, Faulkner K. 1996 Androgen supplementation in eugonadal men with osteoporosis: Effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone 18:171-177.
24. Dobs AS, Hoover DR, Chen MC, Allen R. 1998 Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. J Clin Endocrinol Metab 83:33-39.
25. Prescribing Information for Androderm® (testosterone transdermal system), Watson Laboratories, Corona, CA, June 2001.
26. Prescribing Information for AndroGel® (testosterone gel), Solvay Pharmaceuticals, Marietta, GA, June 2004.
27. Conway AJ, Handelsman DJ, Lording DW, Stuckey B, Zajac JD. 2000 Use, misuse and abuse of androgens: the Endocrine Society of Australia consensus guidelines for androgen prescribing. Med J Aust 172:220-224.
28. Kaufman JM. 2003 The effect of androgen supplementation therapy on the prostate. Aging Male 6:166-174.
29. 21CFR, Federal Control Substances Act, US Congress, 1990.
30. Kelleher S, Turner L, Howe C, Conway AJ, Handelsman J. 1999 Extrusion of testosterone pellets: a randomized controlled clinical study. Clin Endocrinol 511:469-471.
31. Prescribing Information for Testoderm® (testosterone transdermal), Alza Corporation, Mountain View, CA, May 2003.
32. Hammett-Stabler CA. 2004 The use of biochemical markers in osteoporosis. Clin Lab Med 24:175-197.
33. Meeks ML, Mahaffey KW, Katz MD. 1992 Danazol increases the anticoagulant effect of warfarin. Ann Pharmacother 26:641-642.
34. Goffin E, Pirson Y, Geubel A, van Ypersele de Strihou C. 1991 Cyclosporine-methyltestosterone interaction. Nephron 59:174-175.
35. Marbury T, Hamill E, Bachand R, Sebree T, Smith T. 2003 Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim™, compared to AndroGel®. Biopharm Drug Dispos 24:1125-20.
36. Davison SL, Davis SR. 2003 Androgens in women. J Ster Biochem Mol Biol 85:363-366.
37. Cameron DR, Braunstein GD. 2004 Androgen replacement therapy in women. Fertil Steril 82:273-289.
38. Zumoff B, Strain GW, Miller LK, Rosner W. 1995 Twenty-four hour mean plasma testosterone concentrations decline with age in normal premenopausal women. J Clin Endocrinol Metab 80:1429-1430.
39. Rozenberg S, Bosson D, Peretz A,Caufriez A, Robyn C. 1988 Serum levels of gonadotrophins and steroid hormones in the post-menopause and later life. Maturitas 10:215-224.
40. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. 2000 A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through menopause transition. J Clin Endocrinol Metab 85:2832-2838.
41. Greendale G, Edelstein S, Barrett-Connor E. 1997 Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 12:1833-1843.
42. Steinberg KK, Freni-Titulaer LW, DePuey EG, et al. 1989 Sex steroids and bone density in premenopausal and perimenopausal women. J Clin Endocrinol Metab 69:533-539.
43. Slemenda C, Longcope C, Peacock M, Hui S, Johnston CC. 1996 Sex steroids, bone mass, and bone loss: a prospective study of pre-, peri- and postmenopausal women. J Clin Invest 97:14-21.
44. Jassal SK, Barrett-Connor E, Edelstein S. 1995 Low bioavailable testosterone levels predict future height loss in postmenopausal women. J Bone Min Res 10:650-653.
45. Doldi N, Belvisi L, Bassan M, Fusi F, Ferrari A. 1998 Premature ovarian failure: steroid synthesis and autoimmunity. Gynecol Endocrinol 12:23-28.
46. Anasti J, Kalantaridou SN, Kimzey LM, Defensor RA, Nelson LM. 1998 Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol 91:12-15.
47. Davis SR. 1999 The therapeutic use of androgens in women. J Ster Biochem Mol Biol 69:177-184.
48. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. 1995 Comparison of oral estrogens and estrogens plus androgen in bone mineral density, menopausal symptoms and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 85:529-537.
49. Davis SR, McCloud P, Strauss BJ, Burger H. 1995 Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 21:227-236.
50. Savvas M, Studd JW, Norman S, Leather AT, Garnett TJ, Fogelman I. 1992 Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post menopausal women who have previously received long-term oral oestrogens. Br J Obstet Gynaecol 99:757-760.
51. Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang HM. 1999 A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women: effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 44:1012-1020.
52. Raisz LG, Wiita B, Artis A, et al. 1996 Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 81:37-43.
53. Sands RH, Studd JW, Jones J, Alaghband-Zadeh J. 2000 Comparison of the biochemical effects of testosterone and estrogen on bone markers in surgically menopausal women. Gynecol Endocrinol 14:382-387.
54. Need AG, Horowitz M, Bridges A, Morris HA, Nordin BE. 1989 Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic women. Arch Intern Med 149:57-60.
55. Flicker L, Hopper JL, Larkins RG, Lichtenstein M, Buirski G, Wark JD. 1997 Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis. Osteoporos Int 7:29-35.
56. Erdtsieck RJ, Pols HA, van Kuijk C, Birkenhager-Frenkel DH, Zeelenberg J, Kooy PR 1994 Course of bone mass during and after hormonal replacement therapy with and without addition of nandrolone decanoate. J Bone Miner Res 9:277-283.
57. Chesnut CH 3rd, Ivey JL, Gruber HE, et al. 1983 Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechansims of action. Metabolism 32:571-580.
58. Beringer TR, Ardill J, Taggart HM. 1986 Effect of calcium and stanozolol on calcitonin secretion in patients with femoral neck fracture. Bone Miner 1:289-295.
59. Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, et al. 2002 Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J Clin Endocrinol Metab 87:4935-4941.
60. Labrie F, Diamond P, Cusan L, Gomez J, Belanger A, Candas B. 1997 Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 82:3498-3505.
61. Lobo RA, Rosen RC, Yang HM, Block B, van der Hoop R. 2003 Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 79:1341-1352.
62. Shifren JL. 2004 The role of androgens in female sexual dysfunction. Mayo Clin Proc 79(Suppl 4):S19-S24.
63. Davis SR, Walker KZ, Strauss BJ. 2000 Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. Menopause 7:395-401.
64. Lovejoy JC, Bray FA, Bourgeois MO, et al. 1996 Exogenous androgens influence body composition and regional body fat distribution in obese post-menopausal women: a clinical research center study. J Clin Endocrinol Metab 81:2198-2203.
65. Garnett T, Studd J, Watson N, Savvas M. 1991 A cross-sectional study of the effects of long-term percutaneous hormone replacement therapy on bone density. Obstet Gynecol 78:1002-7.
66. Hickok LR, Toomey C, Speroff L. 1993 A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol 82:919-924.
67. Hampl R, Kancheva R, Hill M, Bicikova M, Vondra K. 2003 Interpretation of sex hormone-binding globulin levels in thyroid disorders. Thyroid 13:755-760.
68. Goldstat R, Briganti E, Tran J. 2003 Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 10:390-398.
69. Pugeat M, Crave JC, Elmidani M, et al. Pathophysiology of sex hormone binding globulin (SHBG): Relation to insulin. J Steroid Biochem Mol Biol 1991;40:841-849.
70. Prescribing Information for Betratest® and Estratest H.S.® (esterified estrogens and methyltestosterone), Solvay Pharmaceuticals, Marietta, GA.
71. McGriff-Lee NJ. 2003 Transdermal testosterone gel (Cellegy). Curr Opin Investig Drugs 3:1629-1632.
72. McGriff N, Pucino F, Csako, G. 2005 Androgenic and anabolic steroid agents. In: McPherson ML, ed. Clinical Pharmacology in Nursing, 1st ed. Lippincott Williams & Wilkins, Philadelphia.